Dachille Douglas A.'s Form 4 filing
BridgeBio Pharma, Inc. (BBIO) · filed Mar 16, 2022
- Accession no.
- 0000899243-22-011246
- Filed
- Mar 16, 2022
- Trade date
- Mar 14, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $81.9K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Dachille Douglas A.CIK 0001652908 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Mar 14, 2022 | Common Stock | PPurchaseAcquired | +10,000 | $8.19F1 | +$81,900 | 20,000 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Represents the weighted average purchase price of the shares purchased from $8.1699 to $8.2084 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares purchased at each separate price for all transactions as reported in this footnote.
Referenced by the price of 1 transaction in Table I.